2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original Research
2014
Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu I, Brunt E. Role of liver biopsy in nonalcoholic fatty liver disease. World Journal Of Gastroenterology 2014, 20: 9026-37. PMID: 25083076, PMCID: PMC4112884, DOI: 10.3748/wjg.v20.i27.9026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseLiver biopsyPediatric nonalcoholic fatty liver diseaseNASH Clinical Research NetworkLocation of fibrosisSpecific histologic lesionsCardiovascular risk factorsExcess alcohol intakeChronic liver diseaseClinical Research NetworkClinical research trialsLiver biopsy evaluationLimitations of biopsyNon-invasive testingImportant liver diseaseHepatic manifestationNecroinflammatory activityMetabolic syndromeAlcohol intakeHistologic findingsHepatic triglyceridesRisk factorsBiopsy evaluation
2012
Hepatic Hemangiopericytoma/Solitary Fibrous Tumor: A Review of Our Current Understanding and Case Study
Bokshan SL, Doyle M, Becker N, Nalbantoglu I, Chapman WC. Hepatic Hemangiopericytoma/Solitary Fibrous Tumor: A Review of Our Current Understanding and Case Study. Journal Of Gastrointestinal Surgery 2012, 16: 2170-2176. PMID: 22854953, DOI: 10.1007/s11605-012-1947-x.Peer-Reviewed Case Reports and Technical NotesConceptsSolitary fibrous tumorProlonged steroid useSoft tissue tumorsSoft tissue neoplasmWorld Health OrganizationAdjuvant radiotherapyHepatic resectionInoperable casesSteroid useIGF-IICurrent mainstayPainless massMost lesionsVascular neoplasmFibrous tumorMarked hypoglycemiaTissue tumorsDiagnostic modalitiesHemangiopericytomaChemotherapeutic approachesMesenchymal originNeoplasmsHealth OrganizationAntiangiogenic compoundsTumorsPositron Emission Tomography with [18F]-3′-Deoxy-3′fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilot Study
Dehdashti F, Grigsby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA. Positron Emission Tomography with [18F]-3′-Deoxy-3′fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilot Study. Molecular Imaging And Biology 2012, 15: 106-113. PMID: 22684813, PMCID: PMC3659775, DOI: 10.1007/s11307-012-0566-y.Peer-Reviewed Original ResearchConceptsDisease-free survivalPositron emission tomographyFDG uptakeFLT uptakeRectal cancerAdvanced resectable rectal cancerEmission tomographyImproved disease-free survivalMaximum standardized uptake valuePercentage changePilot studyResectable rectal cancerAdvanced rectal cancerFDG-PET/Predictors of outcomeStandardized uptake valuePurposeThis pilot studyNeoadjuvant chemoradiotherapyProgressive diseaseRegional lymphResultsThirteen patientsFLT-PETHigher percentage changeTumor uptakeUptake value